Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Ups Private Offering by $100 Million

NEW YORK, Dec. 6 - Invitrogen on Thursday announced that it has increased from $400 million to $500 million its private offering of convertible subordinated notes due 2006.


The company said it plans to use the net for general corporate purposes, including research and development activities and working capital, investments in infrastructure, and potential acquisitions. The transaction is expected to close on Dec. 11.


According to Invitrogen, the notes may be converted at any time into shares of its common stock at a cost of $86.10 per share. The notes, which will accrue 2.25 percent interest per year that will be payable semiannually, will mature in five years and will be callable after Dec. 20.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.